In vivo, HEPG2 xenograft models received bispecific or c-MET-CAR-T, and tumour burden was reduced (but not eliminated) in all mice by the end of the experiment (day 13) compared to control CAR [84]. The gene discussed is MET; the disease is neoplasm.